Zejula Maintenance Therapy Extends Progression-free Survival in Advanced Ovarian Cancer Patients, Phase 3 Trial Shows

Zejula Maintenance Therapy Extends Progression-free Survival in Advanced Ovarian Cancer Patients, Phase 3 Trial Shows
Maintenance treatment with Zejula (niraparib) extended the time without disease worsening in women with advanced ovarian cancer who had responded to first-line chemotherapy, according to updated results of a Phase 3 trial. The study, called PRIMA (NCT02655016), is a randomized, double-blind clinical trial assessing Zejula as a maintenance therapy in 620 women with newly diagnosed ovarian cancer following response to platinum-based chemotherapy. All patients have stage III or IV cancer, meaning it has spread outside the ovaries to the nearby lymph nodes or to other regions in the body. Chemotherapy was given before or after surgery to remove the tumor. Zejula’s starting dose is 200 mg once-daily in patients with baseline weight under 77 kg or a platelet count below 150K/μL, and 300 mg in all other participants. Each treatment cycle lasts 28 days. Besides providing prolonged time without disease progression, or progression-free survival, regardless of the patients’ biomarker status, the results showed that treatment with Zejula was consistent with previous clinical trials in its safety and tolerability. Full results from PRIMA will be presented at an upcoming scientific meeting. Zejula is an oral PARP inhibitor. It is marketed by
Subscribe or to access all post and page content.